Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial.

<h4>Background</h4>Nitazoxanide is widely available and exerts broad-spectrum antiviral activity <i>in vitro</i>. However, there is no evidence of its impact on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.<h4>Methods</h4>In a multicentre, randomised, double-blind, placebo-... View More